Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 6/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 5/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.54 |
| ▸ | ITGAV | P06756 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 3/20 | 0.50 |
| ▸ | KYNU | Q16719 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13530114 | 1.00 | ECE1 (0.57) | ECE1FOLH1SIRT2SIRT1MME | |
| SCHEMBL21174225 | 0.91 | ECE1 (0.54) | ECE1FOLH1SIRT2SIRT1MME | |
| SCHEMBL21174139 | 0.91 | ECE1 (0.54) | ECE1FOLH1SIRT2SIRT1MME | |
| SCHEMBL57729 | 0.91 | ECE1 (0.54) | ECE1FOLH1SIRT2SIRT1MME | |
| SCHEMBL56605 | 0.90 | ECE1 (0.53) | ECE1FOLH1SIRT2SIRT1MME | |
| SCHEMBL8387978 | 0.89 | FOLH1 (0.65) | ECE1FOLH1SIRT2SIRT1ITGB3 | |
| SCHEMBL13530111 | 0.87 | SIRT2 (0.56) | ECE1FOLH1SIRT2SIRT1MME | |
| SCHEMBL10421088 | 0.87 | FOLH1 (0.62) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL12874103 | 0.86 | SIRT2 (0.65) | FOLH1SIRT2SIRT1ITGB3ITGAV | |
| SCHEMBL12247715 | 0.86 | SIRT2 (0.65) | FOLH1SIRT2SIRT1ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | FARDIS MARIA | 2009-06-18 | — | — | US | disclosed |
| US-7470724-B2 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7432261-B2 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432273-B2 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES INC. | 2007-02-01 | — | — | US | disclosed |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | GILEAD SCIENCES, INC. | 2006-09-07 | — | — | US | disclosed |
| EP-1663254-A2 | ANTI-INFLAMATORY PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| WO-2005044308-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | GILEAD SCIENCES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156558-A1 | PHOSPHONATE ANALOGS OF ANTIMETABOLITES | TYMP, PHOSPHO1, PHPT1 | ECE1 1541/4885FOLH1 171/4885SIRT2 3421/4885 |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | ECE1 1693/4885FOLH1 1385/4885SIRT2 1993/4885 |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | ECE1 1693/4885FOLH1 1385/4885SIRT2 1993/4885 |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | PIK3CA, PHOSPHO1, PTEN | ECE1 2821/4885FOLH1 375/4885SIRT2 3197/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | ECE1 831/4885FOLH1 1162/4885SIRT2 3184/4885 |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | TYMP, PHOSPHO1, PHPT1 | ECE1 1541/4885FOLH1 171/4885SIRT2 3421/4885 |
| US-20060199788-A1 | Anti-inflammatory phosphonate compounds | PHOSPHO1, TNF, PTGES | ECE1 831/4885FOLH1 1162/4885SIRT2 3184/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | ECE1 2821/4885FOLH1 375/4885SIRT2 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.